ACTRN12623000345684进行中（未招募）2 期
A Double-Blind, Randomised Placebo-Controlled Feasibility Trial Assessing Oral Cannabis for The Relief of Fibromyalgia Symptoms
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age: greater than or equal to 18 years
- •Able to give written informed consent
- •Able to complete patient-reported outcome measures per the investigator’s discretion
- •At screening, subjects must meet the 2016 American College of Rheumatology (ACR) criteria for FMS:
- •-Widespread pain index (WPI) greater than or equal to 7 and symptom severity score (SSS) greater than or equal to 5, or WPI 4-6 and SSS greater than or equal to 9
- •-Generalised pain, defined as pain in at least 4 of 5 regions, is present.
- •-Symptoms have been generally present for at least 3 months.
- •Average daily pain score (ADPS) greater than or equal to 4 on the 11-point numeric rating scale (NRS) over the past seven days before randomisation (based on completion of at least four daily pain diaries during the 7-day baseline period before randomisation).
- •Participants are willing to ensure that they or their partner use a highly effective contraception method (or combination of two less effective methods ) during the study and for 4 weeks thereafter (applicable to heterosexual female patients of childbearing potential and fertile male patients whose partners are of childbearing potential).
排除标准
- •Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, hematologic illness or cardiovascular disease (e.g., severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months before screening that in the opinion of the investigator would interfere with study participation or assessment of safety and tolerability.
- •Anticipation of initiation or significant change to normal daily exercise routines or need for ongoing use of concomitant medications or non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety.
- •Unable to undergo pre-study washout (30 days or less as assessed by urinary THC test) of prohibited concomitant medications/substances (including cannabis/medicinal cannabis products).
- •Subjects who are at risk of suicide as defined by their responses to the Columbia-Suicide Severity Rating Scale (C-SSRS) or the investigator's opinion. Note: Patients answering yes” to any of the questions about active suicidal ideation/intent/behaviours occurring within the past 12 months will be excluded (C-SSRS Suicide Ideation section – Questions 3, 4, or 5; C-SSRS Suicidal Behaviour section, any of the suicide behaviours questions). Such patients will be directed to a mental health support service.
- •Current moderate severe to severe depression or anxiety disorders as assessed by the Depression Patient Health Questionnaire-9 (PHQ-9, total score of >10) and Generalized Anxiety Disorder-7 questionnaire (GAD-7, total score of >10). Still, mild to moderate depression (PHD-9 total score of 0-10) or anxiety disorders (GAD-7 total score of 0-10) are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study.
- •Any diagnosis of lifetime psychotic or bipolar disorder.
- •Subjects with pain due to other conditions (e.g., diabetic peripheral neuropathic pain or post-herpetic neuralgia) that, in the investigator's opinion, would confound assessment or self-evaluation of the pain associated with FMS.
- •Subjects with pain due to any widespread inflammatory musculoskeletal disorder (e.g., rheumatoid arthritis, lupus) or widespread rheumatic disease other than FMS.
- •Current or history of abuse or dependence on prescription medications, illicit drugs, or heavy alcohol drinking within the past year.
- •Any history of a malignant neoplasm other than benign skin cancers within the past five years.
- •Pregnant or breastfeeding, or intent to become pregnant during the study period or refusing to do pregnancy tests through the study.
- •Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.
- •Known hypersensitivity medical cannabis products. Note: Prior exposure is allowed, as long as hypersensitivity to cannabis was not observed.
- •Known tree nut allergy, particularly walnut allergy.
- •Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator to be unlikely to complete the study.
- •Abnormal investigative tests and laboratory values judged by the investigator to be clinically significant at screening, with particular focus on:
- •a.Abnormal renal function defined as calculated creatinin
研究者
相似试验
已完成
2 期
A Randomised, Double-Blind, Placebo Controlled Feasibility Study of Oral Lorazepam for Symptoms of Anxiety in Patients with Advanced Life-Limiting DiseaseMental Health - AnxietyAnxietyACTRN12620001143910Peter MacCallum Cancer Centre15
进行中（未招募）
1 期
An RSV Human Challenge Study of Palivizumab in Healthy Adult ParticipantsRespiratory Syncytial Virus InfectionMedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001044-26-GBmAbxience Research S.L.56
已完成
1 期
Follow-up study to determine the safety, maximum tolerable dose and ability to provoke an immune response of the Codavax intranasal Influenza Vaccine in healthy adult volunteers..Infection - Studies of infection and infectious agentsInfluenzaACTRN12618002041235Clincial Network Services (CNS) Pty Ltd33
招募中
1 期
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE46 0134 in Healthy VolunteersCancer - Leukaemia - Acute leukaemiaCancerACTRN12623000871640Eilean Therapeutics80
招募中
1 期
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy VolunteersSARS-CoV-2Respiratory - Other respiratory disorders / diseasesACTRN12624000220561Trawsfynydd Therapeutics AU Pty Ltd64